Featured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in STEMI and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and safety of the pentaspline pulsed-field ablation (PFA) catheter.
JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-US
Related Articles
Fierce Medtech’s 2022 Fierce 15
Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of…{post_date: F d, Y}
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Biospace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial…{post_date: F d, Y}
Anumana expands AI cardiac care platform with support from Boston Scientific
Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific. Read more on massdevice.com{post_date: F d, Y}
Anumana Announces Issuance of New American Medical Association CPT® Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithms{post_date: F d, Y}